Trulicity ® (dulaglutide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Trulicity Summary of Product Characteristics (SmPC)

Trulicity® (dulaglutide): Gastric Emptying

Dulaglutide delays gastric emptying and caution should be taken when dulaglutide is concomitantly administered with oral medications.

Information from the label

Dulaglutide delays gastric emptying and has the potential to impact the rate of absorption of concomitantly administered oral medicinal products.1

In clinical pharmacology studies, dulaglutide did not affect the absorption of the orally administered medications tested to any clinically relevant degree. These orally administered medications include warfarin, metformin, lisinopril, metoprolol, digoxin, paracetamol, norelgestromin, ethinylestradiol, sitagliptin, and atorvastatin. 1


Dulaglutide has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.1


1. Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Date of Last Review: January 15, 2018

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question